(19)
(11) EP 2 707 501 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
11.04.2018 Bulletin 2018/15

(45) Mention of the grant of the patent:
28.02.2018 Bulletin 2018/09

(21) Application number: 12720167.1

(22) Date of filing: 09.05.2012
(51) International Patent Classification (IPC): 
C12Q 1/68(2018.01)
(86) International application number:
PCT/EP2012/058502
(87) International publication number:
WO 2012/152811 (15.11.2012 Gazette 2012/46)

(54)

MOLECULAR MARKERS IN PROSTATE CANCER

MOLEKULARE MARKER BEI PROSTATAKARZINOM

MARQUEURS MOLÉCULAIRES DU CANCER DE LA PROSTATE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 12.05.2011 WO PCT/EP2011/057716

(43) Date of publication of application:
19.03.2014 Bulletin 2014/12

(60) Divisional application:
18158356.8

(73) Proprietor: MDxHealth Research B.V.
6534 AT Nijmegen (NL)

(72) Inventor:
  • SMIT, Franciscus, Petrus
    NL-6546 RN Nijmegen (NL)

(74) Representative: van Kooij, Adriaan et al
Arnold & Siedsma Bezuidenhoutseweg 57
2594 AC The Hague
2594 AC The Hague (NL)


(56) References cited: : 
WO-A1-2009/015229
WO-A1-2010/037735
WO-A1-2009/042742
WO-A2-2004/060304
   
  • MICHELLE R. DOWNES ET AL: "Urinary markers for prostate cancer", BJU INTERNATIONAL, vol. 99, no. 2, 1 February 2007 (2007-02-01), pages 263-268, XP055014164, ISSN: 1464-4096, DOI: 10.1111/j.1464-410X.2006.06610.x
  • VAN GILS M P M Q ET AL: "Innovations in Serum and Urine Markers in Prostate Cancer", EUROPEAN UROLOGY, ELSEVIER BV, NL, vol. 48, no. 6, 1 December 2005 (2005-12-01), pages 1031-1041, XP027606458, ISSN: 0302-2838 [retrieved on 2005-12-01]
  • TALESA VINCENZO N ET AL: "Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers", CANCER BIOMARKERS, IOS PRESS, AMSTERDAM, NL, vol. 5, no. 6, 1 January 2009 (2009-01-01) , pages 241-251, XP009148896, ISSN: 1574-0153
  • Bussemakers et al.: "DD3: A New Prostate-specific Gene, highly Overexpressed in Prostate Cancer", , 1 December 1999 (1999-12-01), XP055030609, Retrieved from the Internet: URL:http://cancerres.aacrjournals.org/cont ent/59/23/5975.full.pdf [retrieved on 2012-06-21]
  • YVES FRADET ET AL: "uPM3, a new molecular urine test for the detection of prostate cancer", UROLOGY, vol. 64, no. 2, 1 August 2004 (2004-08-01) , pages 311-315, XP055030611, ISSN: 0090-4295, DOI: 10.1016/j.urology.2004.03.052
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).